

Roberto Marasca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5473727/publications.pdf>

Version: 2024-02-01

238
papers

10,401
citations

38742

50
h-index

38395

95
g-index

242
all docs

242
docs citations

242
times ranked

10131
citing authors

#	ARTICLE	IF	CITATIONS
1	PEG-Asparaginase Single-Agent Rescue in an Advanced Case of Monomorphic Epitheliotropic Intestinal T Cell Lymphoma. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 304-308.	1.3	0
2	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	1.4	49
3	BTK Inhibitors Impair Platelet-Mediated Antifungal Activity. <i>Cells</i> , 2022, 11, 1003.	4.1	7
4	Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia via Kynurenine/Aryl Hydrocarbon Receptor-Mediated MCL1 Modulation. <i>Frontiers in Immunology</i> , 2022, 13, 832263.	4.8	6
5	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. <i>Cancers</i> , 2022, 14, 207.	3.7	3
6	The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5242.	4.1	7
7	Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study. <i>Blood Cancer Journal</i> , 2022, 12, 79.	6.2	1
8	Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. <i>Blood Advances</i> , 2022, 6, 3875-3878.	5.2	2
9	Nurse-Like Cells and Chronic Lymphocytic Leukemia B Cells: A Mutualistic Crosstalk inside Tissue Microenvironments. <i>Cells</i> , 2021, 10, 217.	4.1	19
10	Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1906.	4.1	19
11	IRF4 modulates the response to BCR activation in chronic lymphocytic leukemia regulating IKAROS and SYK. <i>Leukemia</i> , 2021, 35, 1330-1343.	7.2	13
12	Cytomegalovirus reactivation after hematopoietic stem cell transplant with CMV \propto IG prophylaxis: A monocentric retrospective analysis. <i>Journal of Medical Virology</i> , 2021, 93, 6292-6300.	5.0	3
13	Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection. <i>Haematologica</i> , 2021, 106, 2265-2268.	3.5	6
14	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	1.7	8
15	A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib. <i>Leukemia and Lymphoma</i> , 2021, 62, 2018-2021.	1.3	2
16	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3027-3036.	1.4	40
17	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID \propto 19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021, 39, 570-574.	1.7	9
18	Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9159.	4.1	7

#	ARTICLE	IF	CITATIONS
19	IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC. <i>Hematological Oncology</i> , 2021, 39, 707-711.	1.7	5
20	How to Improve Prognostication in Acute Myeloid Leukemia with CBFMB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring. <i>Biomedicines</i> , 2021, 9, 953.	3.2	6
21	Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. <i>Cancers</i> , 2021, 13, 4582.	3.7	28
22	Pre-existing cytopenia heralding de novo acute myeloid leukemia: uncommon presentation of NPM1-mutated AML in a single-center study. <i>Leukemia Research</i> , 2021, 111, 106747.	0.8	0
23	Early palliative/supportive care in acute myeloid leukaemia allows low aggression end-of-life interventions: observational outpatient study. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2021-002898.	1.6	12
24	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	7.2	57
25	An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920). <i>Blood</i> , 2021, 138, 3746-3746.	1.4	1
26	Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1. <i>Frontiers in Oncology</i> , 2021, 11, 777587.	2.8	9
27	Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections. <i>Blood Reviews</i> , 2020, 40, 100635.	5.7	29
28	Selective inhibition of PI3K \hat{I}^3 affects survival and proliferation of chronic lymphocytic leukemia B cells. <i>Leukemia and Lymphoma</i> , 2020, 61, 455-459.	1.3	1
29	Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. <i>Haematologica</i> , 2020, 105, 1937-1947.	3.5	29
30	NPM1-Mutated Myeloid Neoplasms with 20% Blasts: A Really Distinct Clinico-Pathologic Entity?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8975.	4.1	26
31	Investigating the association between physicians self-efficacy regarding communication skills and risk of "burnout". <i>Health and Quality of Life Outcomes</i> , 2020, 18, 271.	2.4	32
32	Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center study. <i>Annals of Hematology</i> , 2020, 99, 2201-2203.	1.8	3
33	BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 2158.	4.8	30
34	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. <i>Blood</i> , 2020, 136, 763-766.	1.4	33
35	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	7.2	198
36	Acute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer Answers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1081.	4.1	10

#	ARTICLE	IF	CITATIONS
37	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	3.5	64
38	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. <i>HemaSphere</i> , 2020, 4, e395.	2.7	4
39	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020, 136, 47-49.	1.4	1
40	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020, 136, 23-25.	1.4	0
41	Mutations of the <i>Exportin 1 (XPO1)</i> Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. <i>Training/Validation Study</i> . <i>Blood</i> , 2020, 136, 31-32.	1.4	1
42	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	1.4	2
43	Indoleamine 2,3-Dioxygenase Mediates Survival of Chronic Lymphocytic Leukemia B Cells through Aryl Hydrocarbon Receptor By Inducing Mcl1. <i>Blood</i> , 2020, 136, 19-19.	1.4	0
44	Characterization of Duvelisib in Patients with Refractory Marginal Zone Lymphoma: Data from the Phase 2 DYNAMO Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S312-S313.	0.4	1
45	Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e321-e323.	0.4	0
46	Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. <i>Oncotarget</i> , 2019, 10, 869-882.	1.8	25
47	Lenalidomide in Pretreated Patients with Diffuse Large B Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. <i>Oncologist</i> , 2019, 24, 1246-1252.	3.7	10
48	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019, 3, 4280-4290.	5.2	66
49	Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS. <i>Leukemia</i> , 2019, 33, 1278-1302.	7.2	10
50	Peripheral lymphadenopathy: role of excisional biopsy in differential diagnosis based on a five-year experience. <i>Minerva Chirurgica</i> , 2019, 74, 218-223.	0.8	4
51	NOTCH2 Contributes to Venetoclax Resistance in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 4280-4280.	1.4	3
52	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	1.7	55
53	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study). <i>Oncologist</i> , 2018, 23, 1033-1038.	3.7	3
54	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	3.5	30

#	ARTICLE	IF	CITATIONS
55	Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study. <i>Leukemia and Lymphoma</i> , 2018, 59, 225-228.	1.3	3
56	Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. <i>Leukemia and Lymphoma</i> , 2018, 59, 423-433.	1.3	7
57	Angiopoietin-2 acts as a survival factor for chronic lymphocytic leukemia B cells throughout T cell receptor engagement. <i>Hematological Oncology</i> , 2018, 36, 372-375.	1.7	0
58	Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3492.	4.1	52
59	Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia. <i>Haematologica</i> , 2018, 103, e598-e601.	3.5	16
60	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018, 132, 922-922.	1.4	2
61	Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 585-585.	1.4	7
62	Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. <i>Oncotarget</i> , 2018, 9, 23443-23450.	1.8	12
63	Casein kinase 1: a new tale of chronic lymphocytic leukemia (CLL) microenvironment. <i>Translational Cancer Research</i> , 2018, 7, S730-S732.	1.0	0
64	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib within a Named Patient Program (NPP) in Italy. a Real-Life Retrospective Study. <i>Blood</i> , 2018, 132, 3147-3147.	1.4	1
65	The importance of cytogenetic and molecular analyses in eosinophilia-associated myeloproliferative neoplasms: an unusual case with normal karyotype and TNIP1- PDGFRB rearrangement and overview of PDGFRB partner genes. <i>Leukemia and Lymphoma</i> , 2017, 58, 489-493.	1.3	18
66	The expression of endothelin-1 in chronic lymphocytic leukemia is controlled by epigenetic mechanisms and extracellular stimuli. <i>Leukemia Research</i> , 2017, 54, 17-24.	0.8	8
67	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. <i>Haematologica</i> , 2017, 102, e352-e355.	3.5	9
68	BCR-ABL specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. <i>Blood</i> , 2017, 129, 582-586.	1.4	49
69	Detection of Fusarium-specific T cells in hematologic patients with invasive fusariosis. <i>Journal of Infection</i> , 2017, 74, 314-318.	3.3	7
70	Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S11-S12.	0.4	0
71	Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e9.	0.4	0
72	A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. <i>American Journal of Hematology</i> , 2017, 92, 82-87.	4.1	27

#	ARTICLE	IF	CITATIONS
73	Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 90013-90027.	1.8	5
74	New players in the Brutonâ€™s tyrosine kinase vs. ibrutinib match. <i>Translational Cancer Research</i> , 2017, 6, S469-S471.	1.0	0
75	Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 65968-65981.	1.8	84
76	Allâ€™trans retinoic acid (ATRA) in nonâ€™promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with lowâ€™dose Araâ€™C in three elderly patients with NPM1 â€™mutated AML unfit for intensive chemotherapy and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 1138-1146.	0.5	7
77	Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. <i>Blood</i> , 2016, 127, 2833-2840.	1.4	207
78	The genetics of nodal marginal zone lymphoma. <i>Blood</i> , 2016, 128, 1362-1373.	1.4	147
79	Chronic and recurrent benign lymphadenopathy without constitutional symptoms associated with human herpesvirusâ€™6B reactivation. <i>British Journal of Haematology</i> , 2016, 172, 561-572.	2.5	6
80	The bone marrow represents an enrichment site of specific T lymphocytes against filamentous fungi. <i>Medical Mycology</i> , 2016, 54, 327-332.	0.7	2
81	Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 291-302.	4.4	12
82	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2016, 57, 1823-1830.	1.3	30
83	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. <i>Blood</i> , 2016, 128, 2038-2038.	1.4	3
84	Mucorales-Specific T Cells in Patients with Hematologic Malignancies. <i>PLoS ONE</i> , 2016, 11, e0149108.	2.5	40
85	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. <i>Blood</i> , 2016, 128, 3240-3240.	1.4	0
86	A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line. <i>Blood</i> , 2016, 128, 3076-3076.	1.4	0
87	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , 2015, 125, 1922-1931.	1.4	53
88	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	1.4	197
89	Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma. <i>Haematologica</i> , 2015, 100, e467-e470.	3.5	9
90	Targeting neoplastic B cells and harnessing microenvironment: the â€™double faceâ€™ of ibrutinib and idelalisib. <i>Journal of Hematology and Oncology</i> , 2015, 8, 60.	17.0	49

#	ARTICLE	IF	CITATIONS
91	Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, 253-262.	3.5	40
92	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	1.2	72
93	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. <i>Haematologica</i> , 2015, 100, 511-516.	3.5	42
94	First report of <i>FIP1L1-PDGFRβ</i> -positive eosinophilic granulomatosis with polyangiitis : Fig. 1. <i>Rheumatology</i> , 2015, 54, 1751-1753.	1.9	13
95	NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2015, 56, 3222-3226.	1.3	23
96	Epidemiology and clinical outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: a retrospective single center study. <i>Annals of Hematology</i> , 2015, 94, 1931-1934.	1.8	5
97	The Kr μ ppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. <i>Leukemia</i> , 2015, 29, 503-507.	7.2	84
98	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice, the Lenamant Study. <i>Blood</i> , 2015, 126, 3946-3946.	1.4	3
99	Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up. <i>Blood</i> , 2015, 126, 510-510.	1.4	16
100	A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8573-8573.	1.6	7
101	Ibrutinib Targets Nurse-like Cells Supporting an Immunosuppressive Phenotype in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 613-613.	1.4	0
102	Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor. <i>PLoS ONE</i> , 2014, 9, e98818.	2.5	33
103	Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis. <i>Leukemia and Lymphoma</i> , 2014, 55, 2207-2208.	1.3	5
104	An unusual case of B-ALL occurring in a patient with acute promyelocytic leukemia in remission after two hematopoietic SCTs: whose are the leukemic cells?. <i>Bone Marrow Transplantation</i> , 2014, 49, 1237-1238.	2.4	0
105	Long-term molecular remission with persistence of <i>BCR</i> \cdot <i>ABL</i> \cdot 1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia \cdot positive <i>ALL</i> . <i>British Journal of Haematology</i> , 2014, 164, 299-302.	2.5	8
106	Severe anemia in a patient with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2014, 83, 374-375.	1.1	6
107	Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a CIMEMA Multicenter Phase II Trial. <i>Leukemia</i> , 2014, 28, 642-648.	7.2	57
108	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. <i>Journal of Clinical Oncology</i> , 2014, 32, 634-640.	1.6	198

#	ARTICLE	IF	CITATIONS
109	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. <i>Leukemia Research</i> , 2014, 38, 198-203.	0.8	4
110	Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2014, 42, 126-136.e1.	0.4	23
111	NOX-A12: mobilizing CLL away from home. <i>Blood</i> , 2014, 123, 952-953.	1.4	28
112	Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients. <i>Blood</i> , 2014, 124, 3074-3074.	1.4	1
113	The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes. <i>Blood</i> , 2014, 124, 705-705.	1.4	8
114	Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. <i>ELife</i> , 2014, 3, .	6.0	43
115	The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy. <i>Blood</i> , 2014, 124, 4740-4740.	1.4	0
116	Lenalidomide Promotes a Pro-Inflammatory Switch of Nurse-like Cells Derived from Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3286-3286.	1.4	0
117	A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3300-3300.	1.4	0
118	Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. <i>Annals of Oncology</i> , 2013, 24, 1378-1384.	1.2	13
119	Promoter methylation patterns in <i>Richter syndrome</i> affect stem cell maintenance and cell cycle regulation and differ from <i>de novo</i> diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 194-204.	2.5	19
120	Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. <i>Blood</i> , 2013, 122, 2673-2682.	1.4	208
121	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 1403-1412.	1.4	420
122	The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. <i>Haematologica</i> , 2013, 98, 1115-1123.	3.5	92
123	<i>MGA</i> , a suppressor of <i>MYC</i> , is recurrently inactivated in high risk chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1087-1090.	1.3	81
124	<i>ANGPT2</i> promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia. <i>Epigenetics</i> , 2013, 8, 720-729.	2.7	30
125	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4902-4905.	1.4	113
126	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. <i>Haematologica</i> , 2013, 98, 980-987.	3.5	193

#	ARTICLE	IF	CITATIONS
127	Clinical heterogeneity of <i>de novo</i> 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. <i>Hematological Oncology</i> , 2013, 31, 88-95.	1.7	25
128	Characterization of Specific Immune Responses to Different <i>Aspergillus</i> Antigens during the Course of Invasive <i>Aspergillosis</i> in Hematologic Patients. <i>PLoS ONE</i> , 2013, 8, e74326.	2.5	48
129	The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells. <i>PLoS ONE</i> , 2013, 8, e83830.	2.5	80
130	A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study. <i>Blood</i> , 2013, 122, 1645-1645.	1.4	2
131	A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 687-687.	1.4	15
132	Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. <i>Blood</i> , 2013, 122, 77-77.	1.4	0
133	Pathogenetic Mechanisms of Hepatitis C Virus-Induced B-Cell Lymphomagenesis. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	20
134	Physical contact with endothelial cells through $\alpha 1$ - and $\alpha 2$ - integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. <i>Haematologica</i> , 2012, 97, 952-960.	3.5	29
135	NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. <i>Haematologica</i> , 2012, 97, 437-441.	3.5	178
136	The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development. <i>Journal of Experimental Medicine</i> , 2012, 209, 1537-1551.	8.5	363
137	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. <i>Haematologica</i> , 2012, 97, 849-853.	3.5	14
138	Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. <i>Blood</i> , 2012, 119, 521-529.	1.4	394
139	Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. <i>Hematological Oncology</i> , 2012, 30, 46-49.	1.7	20
140	Atraumatic splenic rupture in patients with myelodysplastic syndromes: Report of a case occurred during treatment with 5-azacitidine and review of the literature. <i>Leukemia Research</i> , 2012, 36, e52-e56.	0.8	3
141	Different impact of <i>NOTCH1</i> and <i>SF3B1</i> mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2012, 158, 426-429.	2.5	90
142	IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. <i>Journal of Translational Medicine</i> , 2012, 10, 18.	4.4	21
143	Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2012, 120, 200-200.	1.4	13
144	Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 712-712.	1.4	0

#	ARTICLE	IF	CITATIONS
145	In Vitro and in Vivo Evidence of an Anti-Angiogenic Effect of Lenalidomide in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1782-1782.	1.4	2
146	The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. <i>Blood</i> , 2011, 117, 3391-3401.	1.4	316
147	Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 986-993.	1.6	302
148	Analysis of the chronic lymphocytic leukemia coding genome: role of <i>NOTCH1</i> mutational activation. <i>Journal of Experimental Medicine</i> , 2011, 208, 1389-1401.	8.5	565
149	May the Indirect Effects of CMV-6 in Transplant Patients be Exerted Through the Reactivation of the Viral Replicative Machinery?. <i>Transplantation</i> , 2011, 92, e49-e51.	1.0	6
150	Alteration of BIRC3 and multiple other NF- κ B pathway genes in splenic marginal zone lymphoma. <i>Blood</i> , 2011, 118, 4930-4934.	1.4	176
151	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	1.4	173
152	Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. <i>Blood</i> , 2011, 118, 5416-5419.	1.4	102
153	B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the <i>IGHV3</i> subgroup gene usage. <i>British Journal of Haematology</i> , 2011, 153, 3-14.	2.5	30
154	A variant of the <i>LRP4</i> gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. <i>British Journal of Haematology</i> , 2011, 152, 284-294.	2.5	28
155	Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. <i>British Journal of Haematology</i> , 2011, 153, 351-357.	2.5	19
156	Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2011, 154, 590-599.	2.5	40
157	Chronic eosinophilic leukaemia with ETV6-NTRK3 fusion transcript in an elderly patient affected with pancreatic carcinoma. <i>European Journal of Haematology</i> , 2011, 86, 352-355.	2.2	22
158	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 633-643.	2.8	67
159	Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2011, 29, 91-99.	1.7	30
160	A case of JAK2 V617F-positive myelodysplastic/myeloproliferative neoplasm with unusual morphology, resembling acute promyelocytic leukemia-like disorder with a chronic course. <i>Leukemia and Lymphoma</i> , 2011, 52, 2012-2019.	1.3	1
161	Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. <i>Blood</i> , 2011, 118, 5759-5766.	1.4	34
162	Alteration of BIRC3 and Multiple Other NF- κ B Pathway Genes in Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2011, 118, 264-264.	1.4	1

#	ARTICLE	IF	CITATIONS
163	SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). <i>Blood</i> , 2011, 118, 263-263.	1.4	1
164	The PI3 Kinase Î Inhibitor, CAL-101 (GS-1101), Inhibits Chronic Lymphocytic Leukemia (CLL) Cell Survival in Endothelial and Marrow Stromal Cell Co-Cultures.. <i>Blood</i> , 2011, 118, 1769-1769.	1.4	1
165	Richter Syndrome (RS): Genome-Wide Promoter Methylation Profile Differs From De Novo Diffuse Large B-Cell Lymphoma (DLBCL) and Affects Genes Involved in Stem-Cell Maintenance and TP53 Pathway. <i>Blood</i> , 2011, 118, 1359-1359.	1.4	17
166	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , 2010, 95, 1792-1796.	3.5	91
167	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. <i>Leukemia and Lymphoma</i> , 2010, 51, 822-838.	1.3	9
168	Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. <i>Blood</i> , 2010, 116, 584-592.	1.4	51
169	Circulating endothelial cells in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2010, 116, 1926-1937.	4.1	29
170	Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. <i>Leukemia Research</i> , 2010, 34, 312-321.	0.8	48
171	<i>IGHD3â€3</i> fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010, 149, 299-302.	2.5	1
172	correspondence: Pregnancy in PNH: another eculizumab baby. <i>British Journal of Haematology</i> , 2010, 150, 707-708.	2.5	37
173	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2010, 151, 435-439.	2.5	20
174	Expression of Mutated <i>IGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. <i>Clinical Cancer Research</i> , 2010, 16, 620-628.	7.0	44
175	Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0). <i>Blood</i> , 2010, 116, 1371-1371.	1.4	2
176	SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. <i>Blood</i> , 2010, 116, 3611-3611.	1.4	4
177	13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 3578-3578.	1.4	0
178	The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship. <i>Blood</i> , 2010, 116, 3601-3601.	1.4	0
179	Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Clinical Cancer Research</i> , 2009, 15, 4415-4422.	7.0	189
180	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009, 144, 492-506.	2.5	106

#	ARTICLE	IF	CITATIONS
181	Vorinostat interferes with Wnt and NF- κ B pathways in the M-07e cell line. <i>Leukemia</i> , 2009, 23, 1935-1938.	7.2	4
182	Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. <i>Journal of Translational Medicine</i> , 2009, 7, 76.	4.4	41
183	Chronic Lymphocytic Leukemia Subset Expressing Mutated IGHV3-23 Has Peculiar Clinical and Biological Features.. <i>Blood</i> , 2009, 114, 1256-1256.	1.4	1
184	Angiotensin-2 Plasma Dosage Predicts Time to First Treatment (TTFT) and Overall Survival (OS) in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 1260-1260.	1.4	0
185	Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome.. <i>Blood</i> , 2009, 114, 760-760.	1.4	0
186	Increased expression of angiotensin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis. <i>Leukemia Research</i> , 2008, 32, 593-597.	0.8	22
187	Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: An ex vivo study. <i>Leukemia Research</i> , 2008, 32, 1324-1325.	0.8	3
188	Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines. <i>Leukemia</i> , 2008, 22, 628-631.	7.2	11
189	Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. <i>British Journal of Haematology</i> , 2008, 142, 529-537.	2.5	78
190	BK virus infection and neurologic dysfunctions in a patient with lymphoma treated with chemotherapy and rituximab. <i>European Journal of Haematology</i> , 2008, 81, 244-245.	2.2	12
191	Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. <i>Haematologica</i> , 2008, 93, 1252-1255.	3.5	19
192	Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405 Study. <i>Blood</i> , 2008, 112, 3167-3167.	1.4	2
193	A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients. <i>Blood</i> , 2008, 112, 652-652.	1.4	33
194	Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Blood</i> , 2008, 112, 778-778.	1.4	0
195	Comprehensive characterization of IGHV3-21 κ expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. <i>Blood</i> , 2007, 109, 2989-2998.	1.4	62
196	Angiotensin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status. <i>Leukemia</i> , 2007, 21, 1312-1315.	7.2	14
197	Incidence and Outcome of Myelodysplastic Syndromes in Province of Modena.. <i>Blood</i> , 2007, 110, 4610-4610.	1.4	1
198	Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience.. <i>Blood</i> , 2007, 110, 3089-3089.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Unfavourable Outcome and Heterogeneity of Partner Chromosomes in Chronic Lymphocytic Leukemia with 14q32/IGH Translocations.. Blood, 2007, 110, 4686-4686.	1.4	0
200	Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood, 2006, 107, 2889-2894.	1.4	167
201	Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with Flt3 mutational status. Leukemia, 2006, 20, 103-114.	7.2	42
202	Angiopoietin-2 Expression in B-Cell Chronic Lymphocytic Leukemia: Association with Clinical Outcome and Immunoglobulin Heavy-Chain Mutational Status.. Blood, 2006, 108, 2780-2780.	1.4	4
203	Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin's Lymphoma: A Multicenter Italian Experience. Journal of Clinical Oncology, 2005, 23, 468-473.	1.6	241
204	Immunoglobulin Mutational Status Detected through Single-Round Amplification of Partial VH Region Represents a Good Prognostic Marker for Clinical Outcome in Chronic Lymphocytic Leukemia. Journal of Molecular Diagnostics, 2005, 7, 566-574.	2.8	12
205	Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia. Leukemia, 2002, 16, 955-956.	7.2	18
206	Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood, 2002, 99, 1482-1485.	1.4	94
207	Immunoglobulin Gene Mutations and Frequent Use of VH1-69 and VH4-34 Segments in Hepatitis C Virus-Positive and Hepatitis C Virus-Negative Nodal Marginal Zone B-Cell Lymphoma. American Journal of Pathology, 2001, 159, 253-261.	3.8	148
208	BCR-ABL rearrangement is not detectable in essential thrombocythemia. Blood, 2001, 97, 2187-2189.	1.4	21
209	Late-Appearing PML/RAR α Fusion Transcript with Coincidental t(12;13)(p13.2;q14) in Acute Promyelocytic Leukemia Lacking the t(15;17) Cytogenetic Anomaly. Cancer Genetics and Cytogenetics, 2000, 119, 121-126.	1.0	7
210	Nonmalignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation. Blood, 2000, 96, 2355-2357.	1.4	46
211	Bone Marrow Failure Associated with Human Herpesvirus 8 Infection after Transplantation. New England Journal of Medicine, 2000, 343, 1378-1385.	27.0	224
212	Gestational thrombocytopenia. Lancet, The, 2000, 356, 1355.	13.7	0
213	The oncogenic 30 and 69 bp deletion variants of the EBV LMP-1 gene are common in HIV-negative lymphoproliferations, both malignant and benign. Annals of Oncology, 1999, 10, 467-469.	1.2	6
214	Expression of Cell-Homologous Genes of Human Herpesvirus-8 in Human Immunodeficiency Virus-Negative Lymphoproliferative Diseases. Blood, 1999, 94, 2931-2933.	1.4	22
215	Lack of confirmation of an association between HTLV-I infection and myelodysplastic syndrome. British Journal of Haematology, 1999, 105, 1146-1147.	2.5	5
216	Human Herpesvirus 6 Latently Infects Early Bone Marrow Progenitors In Vivo. Journal of Virology, 1999, 73, 754-759.	3.4	122

#	ARTICLE	IF	CITATIONS
217	Chronic myeloid leukemia with thrombocytopenic onset may be associated with different BCR/ABL variant transcripts. <i>Cancer Genetics and Cytogenetics</i> , 1998, 101, 75-77.	1.0	9
218	Expression of Human Herpesvirus-6 Antigens in Benign and Malignant Lymphoproliferative Diseases. <i>American Journal of Pathology</i> , 1998, 153, 815-823.	3.8	145
219	Polymerase Chain Reaction Detection of Human Herpesvirus 8 Sequences in Primary Central Nervous System Lymphomas. <i>Journal of Infectious Diseases</i> , 1998, 177, 520-520.	4.0	2
220	Clinico-pathological characterization of hepatitis C virus-related B-cell non-Hodgkin's lymphomas without symptomatic cryoglobulinemia. <i>Annals of Oncology</i> , 1998, 9, 495-498.	1.2	93
221	Might Essential Thrombocythemia Carry Ph Anomaly?. <i>Blood</i> , 1998, 91, 3084-3085.	1.4	19
222	Relationship Between BCR/ABL Fusion Proteins and Leukemia Phenotype. <i>Blood</i> , 1997, 89, 3889-3889.	1.4	11
223	Hepatitis C virus-induced leuko-thrombocytopenia and haemolysis. , 1997, 53, 182-184.		10
224	HHV-8-associated primary cerebral B-cell lymphoma in HIV-negative patient after long-term steroids. <i>Lancet, The</i> , 1996, 347, 980.	13.7	18
225	Frequency and distribution of herpesvirus-like DNA sequences (KSHV) in different stages of classic Kaposi's sarcoma and in normal tissues from an Italian population. , 1996, 66, 427-431.		39
226	Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. <i>British Journal of Haematology</i> , 1996, 94, 373-375.	2.5	121
227	P53 Gene Mutations in Chronic Myelogenous Leukemia Medullary and Extramedullary Blast Crisis. <i>Leukemia and Lymphoma</i> , 1996, 24, 175-182.	1.3	8
228	Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of human peripheral blood mononuclear cells in vivo. <i>Journal of Medical Virology</i> , 1995, 46, 178-188.	5.0	117
229	Human herpesvirus-6: A survey of presence and distribution of genomic sequences in normal brain and neuroglial tumors. <i>Journal of Medical Virology</i> , 1995, 47, 105-111.	5.0	84
230	Spontaneous loss of ph chromosome with maintenance of clonal hemopoiesis in an untreated patient with myeloproliferative disease and a long survival. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 237-240.	2.8	1
231	p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. <i>Journal of Pathology</i> , 1995, 176, 45-53.	4.5	65
232	Detection of PML-RAR α fusion transcript in Ph positive leukemia with acute promyelocytic phenotype lacking the t(15;17) cytogenetic abnormality. <i>Cancer Genetics and Cytogenetics</i> , 1995, 80, 95-99.	1.0	10
233	Human Herpesvirus-6 Genome in Acute Lymphoblastic Leukemia: Evidence against an Etiologic Relationship. <i>Acta Haematologica</i> , 1995, 94, 169-172.	1.4	12
234	HUMAN HERPESVIRUS-6 (HHV-6) IN BLOOD DONORS. <i>British Journal of Haematology</i> , 1995, 89, 943-945.	2.5	6

#	ARTICLE	IF	CITATIONS
235	Double P53 Point Mutation in Extramedullar Blast Crisis of Chronic Myelogenous Leukemia. <i>Leukemia and Lymphoma</i> , 1994, 16, 171-175.	1.3	4
236	Three cases of human herpesvirus-6 latent infection: Integration of viral genome in peripheral blood mononuclear cell DNA. <i>Journal of Medical Virology</i> , 1993, 40, 44-52.	5.0	169
237	Frequent detection of human herpesvirus-6 sequences by polymerase chain reaction in paraffin-embedded lymph nodes from patients with angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. <i>Leukemia Research</i> , 1993, 17, 1003-1011.	0.8	52
238	Human herpesvirus 6 and multiple sclerosis: survey of anti-HHV-6 antibodies by immunofluorescence analysis and of viral sequences by polymerase chain reaction.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993, 56, 917-919.	1.9	99